Abstract:1040 Objectives: Modulation of phosphodiesterase 10A (PDE10A) has shown potential application in the treatment of neurodegenerative and neuropsychiatric disorders such as schizophrenia and Huntington’s disease. A PET tracer for PDE10A would offer non-invasive quantification of its density and distribution in vivo, which could enable target engagement studies for drug discovery. In this study, we aim to identify an aryl 18F-labeled PDE10A PET tracer ([18F]P10A-1910) with facile labeling procedures, high brain uptake, excellent in vivo stability and specificity. Methods: The PDE10A inhibitor P10A-1910 (2-(2-(3-(4-fluorophenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione) and its labeling precursor were prepared in house. [18F]P10A-1910 was labeled by Cu-mediated radiofluorination. Lipophilicity was tested by the shake-flask method. The stability and biodistribution studies were evaluated on CD-1 mice. Dynamic PET scans (0-90 min) were performed in the brain of mature cynomolgus. Results: P10A-1910 and its corresponding precursor were synthesized as colorless solids, with overall yields of 11% and 9%, respectively. [18F]P10A-1910 was produced in 28 ± 3% non-decay-corrected radiochemical yields, with high radiochemical purity (>99%) and high molar activity (>1 Ci/μmol). The LogD value was determined as 3.50, which is appropriate for brain permeability. Ex vivo biodistribution revealed high radioactivity levels in small intestine and liver (>50 %ID/g at 5 min), indicating possible enterohepatic circulation. Radiometabolism analysis showed that [18F]P10A-1910 maintained 80% of parent fraction in mice brain at 30 min post-injection. PET imaging in cynomolgus showed rapid brain uptake and heterogeneous distribution. Specifically, the uptake in the striatum was increased to 1.6 SUV at 3 min, and then slowly decreased to 0.9 SUV at the end of scan, which was consistent with the expression of PDE10A in brain, indicating good specific binding. Conclusions: We have successfully synthesized a new PDE10A PET tracer [18F]P10A-1910 in good radiochemical yields and high molar activities. The biodistribution study, stability testing and preliminary NHP PET imaging data indicated that [18F]P10A-1910 is promising for further evaluation.

Possible Use of 11C-Labeled 8-(3-Chlorostyryl) Caffeine (CSC) Mapping A2A Adenosine Receptors in the CNS and Myocardium

Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain

Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on l-DOPA biotransformation in rat striatum

Development and Preliminary Evaluation of an Aryl 18F-Labeled PET Tracer for Imaging PDE10A

Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis

Radiosynthesis and Evaluation of 4-(6-[18f]fluoro-4-(5-isopropoxy-1h-indazol-3-yl)pyridin-2-yl)morpholine As a Novel Radiotracer Candidate Targeting Leucine-Rich Repeat Kinase 2.

BCAT1 Expression in Hepatocellular Carcinoma

18 F-Labeled PET Tracers Specific for Adenosine A 2A Receptor: Design, Synthesis, and Biological Evaluation

Studies towards the development of a PET radiotracer for imaging of the P2Y1 receptors in the brain: synthesis, 18F-labeling and preliminary biological evaluation

Synthesis, pharmacology and preclinical evaluation of 11C-labeled 1,3-dihydro-2H-benzo[d]imidazole-2-ones for imaging γ8-dependent transmembrane AMPA receptor regulatory protein

Synthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2

A pre-targeting strategy for imaging glucose metabolism using technetium-99m labelled dibenzocyclooctyne derivative.

Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

Development of 11C-Labeled Ω-Sulfhydryl Fatty Acid Tracer for Myocardial Imaging with PET

SPECT vs. PET in cardiac innervation imaging: clash of the titans

Radiosynthesis and Preliminary in Vivo Studies with [11C]SB216763: the First Brain Penetrative PET Tracer for Imaging of Glycogen Synthase Kinase-3 (GSK-3)

Preclinical in vitro and in vivo evaluation of [11C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

68Ga-Labeled Benzothiazole Derivatives for Imaging Aβ Plaques in Cerebral Amyloid Angiopathy

Radiosynthesis and ex vivo evaluation of [11C]-SIB-1553A as a PET radiotracer for beta4 selective subtype nicotinic acetylcholine receptor

AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer